ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen lost $2.21 (47%) to $2.51 on March 1 after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian cancer. The antibody-drug conjugate (ADC) links

Read the full 415 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE